MedPath

Comparison of Duodenal Stenting vs Transpyloric and Duodenal Stenting for Malignant Obstruction

Not Applicable
Completed
Conditions
Duodenal Obstruction
Interventions
Device: Enteral stenting
Registration Number
NCT03125148
Lead Sponsor
Medical College of Wisconsin
Brief Summary

Malignant duodenal obstruction in patients not fit for surgery is treated by placing enteral stents during endoscopy. These patients may also have poor gastric motility. Hence bridging the pyloric opening with the stent along with the duodenal obstruction may deliver better symptomatic improvement. Both approaches are commonly clinically practiced but no formal comparative studies have been done to compare which one is better.

Detailed Description

Enteral self-expanding metal stents are routinely used to palliate malignant gastric outlet obstruction (pancreas cancer, duodenal cancer, gastric cancer and metastasis) in patients not fit for surgical bypass. The technical success in placing these stents approaches \~100% and many of these procedures can be performed in an outpatient setting. However the functional success (patient's ability to eat) is much lower than the technical success. One of the major reasons for this discrepancy is these patients are on narcotics, which are known to be associated with poor gastric motility. At the discretion of the gastroenterologist, FDA approved enteral stents are placed either completely within the duodenum bridging the obstruction or placed across the pyloric opening besides bridging the duodenal obstruction. The significance of this study is to determine if trans-pyloric extension of an intra-duodenal stent facilitates better gastric emptying compared to an intra-duodenal stent without trans-pyloric extension.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
17
Inclusion Criteria

1 - Confirmed diagnosis of cancer

  1. Evidence of a single small bowel obstruction

  2. Considered palliative (can be on narcotics, chemotherapy, and/or radiation therapy)

  3. Not a surgical candidate

  4. >18 years of age

  5. Able to give consent

  6. Eligible for endoscopy (medically fit)

  7. Able to traverse past obstruction with a guidewire

Exclusion Criteria

1 - <18 years of age

  1. Unable to give consent

  2. Pregnant

  3. Have evidence of multiple sites of obstruction in the small bowel

  4. Have evidence of duodenal obstruction secondary to gastric cancer

  5. Ineligible for endoscopy (due to comorbidities or acuity of illness)

  6. Unable to traverse past obstruction with a guidewire

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Enteral stenting intraduodenalEnteral stentingEnteral stent (Wallflex enteral stent) will be placed in the duodenum with the entire stent lying within the duodenum bridging the obstruction.
Enteral stenting transpyloricEnteral stentingEnteral stent (Wallflex enteral stent) will be placed in the duodenum with the stent bridging the obstruction and the pyloric opening with proximal end of the stent lying within the stomach
Primary Outcome Measures
NameTimeMethod
Number of Participants With Any Change (2 Point Increase or Decrease) in Symptoms From BaselineBaseline (before stent) and follow-up (after stent) at 48 hrs (including gastric emptying study) and then symptom follow up at each clinic/telephone visit up to 6 months.

Symptoms of nausea, regurgitation, bloating, fullness, belching, pain, and vomiting were recorded at baseline and then on follow-up after stent placement on a visual analog scale with 0 being no symptoms and 10 being severe symptoms. The visual analog scale used was: 0 No symptom to 10 Severe symptom: Drop by 2 points or more from baseline score after intervention was recorded as "Better" and increase in over 2 points from baseline after intervention was recorded as symptom getting "Worse". A -1 to +1 shift from baseline was considered as "Unchanged".

Gastric emptying was objectively assessed at 48 hours after stent placement with no baseline testing.

Over all quality of life change after stent placement over baseline was a subjective response from the patient as being "Satisfied", "Neutral", "Dissatisfied." Re-interventions and adverse events if any were recorded.

Secondary Outcome Measures
NameTimeMethod
Gastric Emptying48 hours after stent placement

Gastric emptying study test

Technical Success: Stent Placed in the Desired Position as Per RandomizationDay of stent deployment

Successful placement of the stent across the duodenal obstruction with or without trans-pyloric extension as per randomization will determined immediately during endoscopic procedure by endoscopic visualization.

ComplicationsUp to 6 months after stent deployment

Stent related complications

Trial Locations

Locations (1)

Froedtert Hospital

🇺🇸

Milwaukee, Wisconsin, United States

© Copyright 2025. All Rights Reserved by MedPath